Letter to the editor: Vitamin D levels in acute illness and clinical severity in COVID-19 patients

Prateek Lohia1*, Shweta Kapur2, Pragnesh Patel3 and Berhane Seyoum4

Abstract
We would like to comment on the recently published article titled: “Circulating Vitamin D levels status and clinical prognostic indices in COVID-19 patients” by Ricci et al. The authors grouped the patients into two groups according to the vitamin D levels measured at the time of admission into the hospital and reported that lower vitamin D levels are associated with elevated D-dimer and IL-6 levels, low CD4/CD8 ratio and compromised clinical findings with elevated LIPI and SOFA scores. However, review of recent literature shows this association to be debatable. The 25-hydroxyvitamin D levels in the initial phase of critical illness have been reported to drop rapidly and hence consideration of the time of measurement from symptom onset would have enhanced the clinical relevance of these findings. Inferred association between vitamin D levels and disease severity based on SOFA score in COVID-19 patients, needs to be further explored in the light of the recent literature which casts doubt on using SOFA score at admission to predict mortality in COVID-19.

Keywords: COVID-19, SARS-CoV-2, Vitamin D, Inflammation, SOFA, Mortality, 25-Hydroxyvitamin D, Intensive care, Mechanical ventilation, Interleukin-6
significant association between preexisting comorbidities and clinical outcomes in COVID-19 patients [8–11]. In the study by Ricci et al., majority of patients were elderly, but consideration to various preexisting comorbidities and heterogeneity of race is missing, which undermines the clinical relevance of the results of this study.

A number of recent studies suggest inflammatory cytokine especially higher IL-6 associated with COVID-19 severity and survival [12–14]. A review of the literature looking at the association between vitamin D deficiency and IL-6 levels offers mixed evidence. Study by Radujkovic et al.[15] noted elevated IL-6 levels among patients with vitamin D deficiency similar to what has been noted by Ricci et al., whereas several other studies report no such association[16–19]. Similar conflicting results have been noted for elevated d-dimer levels, with many studies reporting no statistical significance [16, 19, 20], thereby further research is needed to elucidate this association as noted by the authors. Additionally Ricci et al. noted increased lung lesions in patients with low vitamin D levels similar to the study by Abrishami et al. [21] wherein they noted higher vitamin D levels associated with decreased amount of lung involvement on imaging, whereas Pizzini et al. [20] noted no such association. Ricci et al. also report that the patients with more severe COVID-19 disease had lower Vitamin D plasma levels regardless of age, whereas there is no mention of any subgroup analysis based on age, or the value of interaction between vitamin D levels and age in their statistical model. Hence it might be prudent to exercise caution while interpreting this statement.

We had earlier conducted a study looking at vitamin D levels and clinical outcomes in COVID-19 patients [22], wherein vitamin D levels were classified as ≥20 ng/mL (patients with normal vitamin D levels) and <20 ng/mL (patients with low vitamin D levels). We found no significant association of vitamin D levels with mortality, the need for mechanical ventilation, intensive care unit (ICU) admission, and thromboembolism in COVID-19. Optimal levels of 25-hydroxyvitamin D for bone and general health have not yet been established [23–25] and most experts agree that vitamin D deficiency should be defined as 25-hydroxyvitamin D of <20 ng/ml [26], it would have been of interest if the authors Ricci et al. had conducted further analysis looking at the results with vitamin D levels <20 ng/mL and ≥20 ng/mL. Our data consisted of COVID-19 positive patients who presented to the hospital and had documented vitamin D, 25-OH level within the past 12 months. In the cohort of our study [22], there were 117 males (43.3%) and 153 females (56.7%). The mean age of patients was 63.81 years (mean ± SD, 14.69). More than half of the patients (n = 139, 51.5%) were in the 65 and older age group, with Blacks being the predominant race (n = 216, 80%). We conducted further exploratory analysis on our data and reclassified vitamin D levels as <10 ng/mL and ≥10 ng/mL (as done by Ricci et al.). Vitamin D level <10 ng/mL was seen in 39 (14.4%) patients and ≥10 ng/mL was seen in 231 (85.6%) patients. After adjusting for age, sex, race, BMI and presence of comorbidities using binary logistic regression, no significant association was seen with mortality (OR = 0.85; 95% CI, 0.33–2.17; p = 0.73), need for ICU admission (OR = 0.95; 95% CI, 0.44–2.06; p = 0.9) or mechanical ventilation (OR = 0.55; 95% CI, 0.20–1.49; p = 0.24).

Additionally, no significant difference was seen in laboratory values (within 24 h of admission using Chi square test)- lymphopenia (Absolute lymphocyte counts less than 1000 per microliter) (17 v/s 111 patients, p = 0.57), ferritin >300 ng/mL (19 v/s 131 patients, p = 0.47) and D-dimer >2 mg/L (15 v/s 76 patients, p = 0.29), between the two groups (patients with vitamin D levels as <10 ng/mL, and patients with vitamin D levels ≥10 ng/mL).

Some of the recent studies note that SOFA score at presentation is less accurate in predicting mortality or the need for mechanical ventilation in COVID-19 patients [27, 28]. In the study by Ricci et al. they note higher SOFA scores in patients with vitamin D levels <10 ng/mL however no significant association with mortality was noted as acknowledged by the authors, we advise a word of caution since the authors report the association between worse outcomes and low vitamin D levels based on elevated SOFA scores.

Notwithstanding these limitations, Ricci et al. illustrate a relationship between low vitamin D levels and inflammatory markers and radiological findings seen in COVID-19 patients. Consideration to address these limitations in future studies would immensely enhance the clinical relevance of these findings. Ideally, vitamin D levels immediately preceding the acute illness should be used to study the association of vitamin D with disease severity. Large community-based studies and randomized clinical trials of vitamin D supplementation in deficiency patients can unravel the enigma of possible role of vitamin D in the disease progression and severity of symptoms in COVID-19 patients.

Abbreviations
IL-6: Interleukin-6; LIPi: Lung Immune Prognosis Index; SOFA: Sequential Organ Failure Assessment; ICU: Intensive care unit; OR: Odds ratio; CI: Confidence interval; SD: Standard deviation.

Acknowledgements
None.

Authors’ contributions
PL conceptualized the letter and performed the lead role in literature review, data analysis, data interpretation, drafting the letter, and reviewing it for critical intellectual content. SK contributed equally towards conceptualization,
literature review, data analysis, data interpretation, drafting the letter, and reviewing it for critical intellectual content. PP and BS helped in conceptualization of the letter, edited and reviewed the letter for critical intellectual content. All the authors read and approved the final letter; agree to be accountable for all aspects of the work.

Funding
None.

Availability of data and materials
The deidentified data that support the findings of this study can be available from the corresponding author upon reasonable request and appropriate permission from the institutional IRB.

Declarations

Ethics approval and consent to participate
The study was exempt by the Detroit Medical Center (DMC) and Wayne State University Institutional Review Board. (IRB application #20-06-2422).

Consent for publication
Not applicable.

Competing interests
All authors declare that they have no competing interests.

Author details
1 Department of Internal Medicine, Wayne State University, 4201 St Antoine, UHC SC, Detroit, MI 48201, USA. 2 Wayne State University, Detroit, MI, USA. 3 Department of Geriatrics, Wayne State University, Detroit, MI, USA. 4 Department of Endocrinology, Wayne State University, Detroit, MI, USA.

Received: 19 March 2021 Accepted: 2 April 2021
Published online: 09 April 2021

References
1. Ricci A, Pagnuca A, D’Ascanio M, Innamorato M, De Vitis C, Mancini R, Giovagnoli S, Facchinato F, Sposato B, Anibaldi P, et al. Circulating Vitamin D levels status and clinical prognostic indices in COVID-19 patients. Respir. Res. 2021;22:76.
2. Kazemi A, Mohammadi V, Aghababaee SK, Golzarand M, Clark CCT, Babafarsho A. Association of Vitamin D status with SARS-CoV-2 infection or COVID-19 severity: a systematic review and meta-analysis. Adv Nutr. 2021. https://doi.org/10.1093/advances/nmab012.
3. Leaf DE, Croy HE, Abraham SJ, Raela A, Waikar SS. Cathelicidin antimicrobial protein, vitamin D, and risk of death in critically ill patients. Crit Care. 2015;19:80.
4. Brook K, Camargo CA, Christopher KB, Quraishi SA. Admission vitamin D status is associated with discharge destination in critically ill surgical patients. Ann Intensive Care. 2015;5:23.
5. Czarnik T, Czarnik A, Gawrda R, Gavor M, Pwoda M, Marszalski M, Maj M, Chrzan Q, Said R, Ruxek-Skora M, et al. Vitamin D kinetics in the acute phase of critical illness: a prospective observational study. J Crit Care. 2018;43:294–9.
6. Yousefzadeh P, Shapses SA, Wang X. Vitamin D binding protein impact on 25-hydroxyvitamin D levels under different physiologic and pathologic conditions. Int J Endocrinol. 2014;2014:981581.
7. Amrein K, Papinutti A, Mathew E, Vila G, Parekh D. Vitamin D and critical illness: what endocrinology can learn from intensive care and vice versa. Endocr Connect. 2018;7:R304–15.
8. Lohia P, Kapur S, Benjaram S, Pandey A, Mir T, Seyoum B. Metabolic Syndrome and clinical outcomes in patients infected with COVID-19: does age, sex and race of the patient with Metabolic Syndrome matter? J Diabete. 2021;13:420–9.
9. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, Ji R, Wang H, Wang Y, Zhou Y. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91–5.
10. Myers LC, Parodi SM, Escobar GJ, Liu VX. Characteristics of hospitalized adults with COVID-19 in an integrated health care system in California. JAMA. 2020;323:2195–8.
11. Gold JAW, Wong KK, Szablewski CM, Patel PR, Rossow J, da Silva J, Natarajan P, Morris SB, Fanfair RN, Rogers-Brown J, et al. Characteristics and clinical outcomes of adult patients hospitalized with COVID-19—Georgia, March 2020. MMWR Morb Mortal Wkly Rep. 2020;69:545–50.
12. Chen LD, Zhang ZY, Wei XJ, Cai YQ, Yao WZ, Wang MH, Huang QF, Zhang XB. Association between cytokine profiles and lung injury in COVID-19 pneumonia. Respir. Res. 2020;21:201.
13. Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, Lavín Y, Swartz TH, Madduri D, Stock A, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020;26:1636–43.
14. Han H, Ma Q, Li C, Liu R, Zhao L, Wang W, Zhang P, Liu X, Gao G, Liu F, et al. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect. 2020;9:123–30.
15. Radujkovic A, Hippchen T, Tihan-Heckler S, Dreher S, Boxbberger M, Merle U. Vitamin D deficiency and outcome of COVID-19 patients. Nutrients. 2020;12:2757.
16. Carpagnano GE, Di Lecce V, Quaranta VN, Zito A, Buonocemo E, Capozza E, Palumbo A, Di Gioia G, Valero VN, Resta O. Vitamin D deficiency as a predictor of poor prognosis in patients with acute respiratory failure due to COVID-19. Endocrinol Invest. 2021;44:6:765–71.
17. Hernández JL, Nan D, Fernandez-Ayala M, García-Unzueta M, Hernández-Hernández MA, López-Hoyos M, Muñoz-Cacho P, Olmos JM, Gutiérrez-Cuadrado M, Ruiz-Cubillán JJ, et al. Vitamin D status in hospitalized patients with SARS-CoV-2 infection. J Clin Endocrinol Metab. 2021;106:e1343–53.
18. Gaudio A, Murabito AR, Agodi A, Monteneri A, Castellino P. Research DOC. Vitamin D levels are reduced at the time of hospital admission in Sicilian SARS-CoV-2-positive patients. Int J Environ Res Public Health. 2021;18(7):3491.
19. Kerget B, Kerget F, Kuzłtung A, Koçak AQ, Araz O, Yılmaz Uçar E, Akgün M. Evaluation of the relationship of serum vitamin D levels in COVID-19 patients with clinical course and prognosis. Tuberk Toraks. 2020;68:227–35.
20. Pizzini A, Aichner M, Sahanic S, Böhm A, Egger A, Hoermann G, Kurz K, Widmann G, Bellmann-Weiler R, Weiss G. Impact of vitamin D deficiency on COVID-19—a prospective analysis from the CovILD registry. Nutrients. 2020;12:2775.
21. Abrishami A, Dalili N, Mohammadib Torbati P, Asgari R, Arab-Ahmadi M, Behnarn B, Sanei-Taheri M. Possible association of vitamin D status with lung involvement and outcome in patients with COVID-19: a retrospective study. Eur J Nutr. 2020. https://doi.org/10.1007/s00394-020-02411-0.
22. Lohia P, Nguyen P, Patel N, Kapur S. Exploring the link between vitamin D and clinical outcomes in COVID-19. Am J Physiol Endocrinol Metab. 2021;320:E520–6.
23. IOM (Institute of Medicine). Dietary reference intakes for calcium and vita- min D. Washington, DC: The National Academies Press. 2011.
24. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266–81.
25. Brown LL, Cohen B, Tabor D, Zappala G, Maruvada P, Coates PM. The vitamin D paradox in Black Americans: a systems-based approach to investigating clinical practice, research, and public health—expert panel meeting report. BMC Proc. 2018;12(Suppl 6):6. https://doi.org/10.1186/s12971-018-0102-4 (eCollection 2018).
26. Holick MF. Vitamin D status: measurement, interpretation, and clinical application. Ann Epidemiol. 2000;9:73–8.
27. Tang X, Du RH, Wang R, Cao TZ, Guan LL, Yang CQ, Zhu Q, Hu M, Li XY, Li Y, et al. Comparison of hospitalized patients with ARDS caused by COVID-19 and H1N1. Chest. 2020;158:195–205.
28. Raschke RA, Agarwal S, Rangan P, Heise CW, Curry SC. Discriminant accuracy of the SOFA score for determining the probable mortality of patients with COVID-19 pneumonia requiring mechanical ventilation. JAMA. 2021. https://doi.org/10.1001/jama.2021.1545.